Luigi Celio

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. pmc Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
    Luigi Celio
    Medical Oncology Unit 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Patient Prefer Adherence 7:391-400. 2013
  2. pmc Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase I
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
    Support Care Cancer 21:565-73. 2013
  3. doi request reprint Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Tumori 98:279-86. 2012
  4. pmc Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
    Luigi Celio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy
    Support Care Cancer 19:1217-25. 2011
  5. ncbi request reprint Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting
    Luigi Celio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 94:447-52. 2008
  6. doi request reprint Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial
    Silvia Damian
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Oncology 84:371-7. 2013
  7. doi request reprint Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial
    Luigi Celio
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Support Oncol 10:65-71. 2012
  8. ncbi request reprint Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Future Oncol 9:1451-8. 2013
  9. doi request reprint Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer
    Vera Cappelletti
    Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
    Endocr Relat Cancer 15:439-49. 2008
  10. ncbi request reprint Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 95:43-7. 2009

Collaborators

Detail Information

Publications17

  1. pmc Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
    Luigi Celio
    Medical Oncology Unit 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Patient Prefer Adherence 7:391-400. 2013
    ....
  2. pmc Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase I
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy
    Support Care Cancer 21:565-73. 2013
    ....
  3. doi request reprint Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Tumori 98:279-86. 2012
    ..We reviewed the current knowledge on the role of palonosetron against acute and delayed emesis in patients with solid tumors undergoing single-day moderately emetogenic chemotherapy regimens...
  4. pmc Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
    Luigi Celio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy
    Support Care Cancer 19:1217-25. 2011
    ....
  5. ncbi request reprint Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting
    Luigi Celio
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 94:447-52. 2008
    ..However, palonosetron may offer advantages of convenience over the short-acting older antagonists due to its ability to be given as a single intravenous dose prior to chemotherapy...
  6. doi request reprint Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial
    Silvia Damian
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Oncology 84:371-7. 2013
    ..The effectiveness of palonosetron without delayed dexamethasone dosing against emesis was investigated in patients scheduled to receive the corticosteroid-containing combination of doxorubicin and paclitaxel (AT) for 3 cycles...
  7. doi request reprint Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial
    Luigi Celio
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Support Oncol 10:65-71. 2012
    ..The non-inferiority of palonosetron plus 1-day versus 3-day dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) due to moderately emetogenic chemotherapy (MEC) has been previously demonstrated...
  8. ncbi request reprint Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials
    Luigi Celio
    Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Future Oncol 9:1451-8. 2013
    ..Data from two randomized trials were pooled to further characterize the effectiveness of palonosetron combined with dexamethasone in the setting of highly emetogenic chemotherapy...
  9. doi request reprint Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer
    Vera Cappelletti
    Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
    Endocr Relat Cancer 15:439-49. 2008
    ..Integration between neo-adjuvant therapy and transcriptional profiling has therefore the potential to identify therapeutic targets to be challenged for overcoming treatment resistance...
  10. ncbi request reprint Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Tumori 95:43-7. 2009
    ..Since there is no internationally adopted standard regimen, we have conducted a pilot study of COI in untreated advanced gastric cancer...
  11. ncbi request reprint Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
    Emilio Bajetta
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133 Milano, Italy
    J Clin Oncol 23:2155-61. 2005
    ..To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer...
  12. ncbi request reprint Neuroendocrine tumors of the larynx: a clinical report and literature review
    Giuseppe Procopio
    Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 92:72-5. 2006
    ..Because of the very low incidence of neuroendocrine tumors in the larynx, a review of the literature has also been performed...
  13. ncbi request reprint Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients
    Vera Cappelletti
    Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Endocr Relat Cancer 11:761-70. 2004
    ....
  14. pmc Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
    Emilio Bajetta
    Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Manag Res 1:89-97. 2009
    ..The present review will discuss the role of palonosetron in the prevention of acute CINV...
  15. doi request reprint Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone
    Emilio Bajetta
    Department of Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Via G Venezian 1, Milan, Italy
    Ann Surg Oncol 16:2985-93. 2009
    ..To determine the long-term outcomes of early-stage Merkel cell carcinoma (MCC) patients managed with surgery alone...
  16. ncbi request reprint Pemetrexed in gastric cancer: clinical experience and future perspectives
    Luigi Celio
    Medical Oncology Unit B and Department of Radiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Semin Oncol 29:63-8. 2002
    ..This article discusses how pemetrexed may be investigated in future clinical trials in gastric cancer...
  17. ncbi request reprint Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
    Leonardo Ferrari
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, I 20133 Milano, Italy
    Int J Oncol 22:1081-9. 2003
    ..The observed variations seem to be mainly linked to the circulating oestrogen levels rather than directly to the way of action of the AI employed...